Table 2. Hemodynamics in BDL rats with thalidomide treatment.
| BDL-cirrhotic rats(n = 6) | Sham rats(n = 5) | |||
|---|---|---|---|---|
| Vehicle (C-V) | Thalidomide (C-T) | Vehicle (S-V) | Thalidomide (S-T) | |
| Body weight (g) | 385±8 | 390±10 | 410±9.7 | 400±13 |
| Mean arterial pressure (MAP, mmHg) | 96.8±5.7 | 101.2±4.6 | 118±9 | 109±12 |
| Heart rate (beats/min) | 341±16 | 329±17 | 238±19 | 227±28 |
| Superior mesenteric arterial blood flow (SMA flow, mL/min) | 11±1.7 | 8.2±0.9* | 5.4±0.8 | 5.6±1.4 |
| Superior mesenteric arterial resistance (SMA resistance, mmHg/mL/min/100g) | 7.4±2 | 10.8±1.3# | - | - |
| Portal venous pressure (PVP, mmHg) | 16±1.9 | 12.5±2.2# | - | - |
| Portal systemic shunting (PSS, %) | 80±14 | 67.2±5* | - | - |
*P<0.05
#P<0.001
because non-cirrhotic sham rats do not develop PPS and our recent study reported that 1-month thalidomide did not change the PVP, only MAP, SMA flow were evaluated to survey whether thalidomide affected the relatively normal splanchnic circulation. SMA resistance is calculated from the formula of (MAP-PVP)/SMA flow. So, the SMA resistance of sham rats cannot be calculated without PVP data.